Actemra Additional Information
Genentech (Roche subsidiary)
Rheumatoid and giant cell arthritis drug
Actemra is an immunoresponsive drug (IL-6 receptor inhibitors) that was approved in 2010, and has been linked to heart attacks, strokes, interstitial lung disease, heat failure, acute pancreatitis, brain bleeds and other life threatening complications.
A report by Statenews.com identified thousands of adverse event reports submitted to the FDA over the past seven years, and has been linked to at least 1,128 deaths.
The Phase 3 clinical study, GIACTA, showed that serious adverse events occurred in 15% (roughly 1:7) patients using Actemra in the study. Competing L-6 receptor inhibitors such as Humira, Enbrel, and Remicade, contain strong warnings against the above side effects. Actemra does not.